|
Description
|
The BIAM-EPI project arises from specific knowledge available to the project proposal group and the will to integrate the existing excellent research cooperation, looking to an optimal and further productive fall-out of Science and Technology in areas impacting on health and quality of life, to be allocated in 2 areas of the Italian Regional Convergence. The partners of the present project proposal intend to create a Temporary Association of Purpose to guarantee a shared approach to the present proposal objectives. Epitech Group has been identified as the leader partner of the project in consideration of the innovative industrial know-how belonging to this company. As per training and education, a fundamental tool of improvement for skills and education in the referred areas, it has been identified a consortium with academic skills staff, to be in charge for this role in line with the project purpose. On the research side, BIAM-EPI plans to develop active raw materials functioning as bioregulators on chronic inflammatory processes or on low-grade inflammation and neuroinflammation. Bioregulators will be developed starting from Aliamides also associated with Polyphenols belonging to Stilbenes and/or Flavons family. Aliamides, endogenous lipidic molecules, are capable to down-regulate genetic transcription factors. Stilbenes and Flavons are molecules naturally present in food; Stilbenes are specifically active on sirtuins during restoration of functional regulation of gene expression. 4 work-packages (WP) contribute to achieve the BIAM-EPI goals. WP1 goal is the design, realization and development of molecules and adducts between active raw materials and a carrier, suitable to be used as bioregulators. Both classes of molecules subject of the study are scarcely hydrophilic, so actions under WP1 will be carried out using advanced technologies for bioavailability optimization, biocompatibility and pharmacokinetic. WP2 is focused on evaluating and characterising effects of bioregulators in experimental models in vitro and in vivo, reproducing same conditions of chronic inflammation or low grade inflammation, in peripheral districts. Activities performed under WP2 will bring to identify bioregulators active on different studied districts, mechanism of action and, to highlight the relation between inflammatory activity and genetic transcription regulation. WP2 actions, notably the use of different experimental models in vivo, some of which are characterized by a low grade inflammation, will allow exploring bioregulators effects also on neuropathic pain, on electroneurographic alterations and on small nervous fibres density. WP3 aims at identify and characterize, with adequate experimental models in vitro and in vivo, bioregulators active on processes of neuroinflammation and neurodegeneration in CNS in experimental models of Cerebral Ischemia, Parkinson’s or Alzheimer’s diseases or Multiple Sclerosis. WP4 aims at studying the application of bioregulators to man through acquisition of specific knowledge on epigenetic alterations in diseases characterized by chronic inflammation and their relation with inflammation marker, clinical symptomatology and functional electroneurographic alterations.
The final goal of BIAM-EPI is getting bioregulators made of active molecules, or association of active molecules, or adduct of active molecules and carriers, having suitable formulations for different analyzed districts, to be bioavailable and well tolerated by the organism, letting innovative therapeutic interventions targeted to counteract chronic inflammation, low-grade inflammation or neuroinflammation deemed as risk factors for the development of several chronic and degenerative diseases. It is fundamental consolidating and strengthen the existing network organization involving different expertises of absolute excellence in a synergic joint work between Partners and Third Subjects, also contributing to further education and employment.
|
Storify
twitter
YouTube